New adult RSV evidence adds context but does not change vaccine eligibility
A VHA observational study estimates mRNA-1345 effectiveness at 24 weeks of 81.8% against hospitalization; its mostly older-male cohort and lower effectiveness against infection among adults 80+ limit generalization. The findings do not change CDC eligibility or establish repeat dosing, and claims of eligibility for at-risk adults 50–74 conflict with current CDC guidance.
Sources (2)
Updated Nov 19, 2026